Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy GT Biopharma stock

Learn how to easily invest in GT Biopharma stock.

GT Biopharma, a company that develops novel immuno-oncology biopharmaceutical drugs, is looking to be listed on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker symbol "GTBP." It hopes to trade on the Nasdaq under the same ticker symbol.

How to buy shares in GT Biopharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GTBP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

GT Biopharma stock price (NASDAQ: GTBP)

Use our graph to track the performance of GTBP stocks over time.

GT Biopharma shares at a glance

Information last updated 2022-09-24.
Latest market close$1.83
52-week range$1.51 - $7.48
50-day moving average $2.56
200-day moving average $2.76
Wall St. target price$4.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.05

Buy GT Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy GT Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GT Biopharma price performance over time

Historical closes compared with the close of $1.825 from 2022-09-28

1 week (2022-09-22) -10.10%
1 month (2022-08-30) -27.00%
3 months (2022-06-30) -38.96%
6 months (2022-03-30) -37.71%
1 year (2021-09-30) -72.92%
2 years (2020-09-29) 773.21%
3 years (2019-09-27) 1,203.57%
5 years (2017-09-29) 5.06

GT Biopharma financials

Gross profit TTM $0
Return on assets TTM -63.91%
Return on equity TTM -123.31%
Profit margin 0%
Book value $0.50
Market capitalisation $58.8 million

TTM: trailing 12 months

GT Biopharma share dividends

We're not expecting GT Biopharma to pay a dividend over the next 12 months.

Have GT Biopharma's shares ever split?

GT Biopharma's shares were split on a 1:17 basis on 11 February 2021. So if you had owned 17 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GT Biopharma shares – just the quantity. However, indirectly, the new 1600% higher share price could have impacted the market appetite for GT Biopharma shares which in turn could have impacted GT Biopharma's share price.

GT Biopharma share price volatility

Over the last 12 months, GT Biopharma's shares have ranged in value from as little as $1.51 up to $7.48. A popular way to gauge a stock's volatility is its "beta".

GTBP.US volatility(beta: 0.55)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GT Biopharma's is 0.5457. This would suggest that GT Biopharma's shares are less volatile than average (for this exchange).

To put GT Biopharma's beta into context you can compare it against those of similar companies.

GT Biopharma overview

GT Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc.

Frequently asked questions

What percentage of GT Biopharma is owned by insiders or institutions?
Currently 15.846% of GT Biopharma shares are held by insiders and 10.249% by institutions.
How many people work for GT Biopharma?
Latest data suggests 8 work at GT Biopharma.
When does the fiscal year end for GT Biopharma?
GT Biopharma's fiscal year ends in December.
Where is GT Biopharma based?
GT Biopharma's address is: 8000 Marina Boulevard, Brisbane, CA, United States, 94005
What is GT Biopharma's ISIN number?
GT Biopharma's international securities identification number is: US36254L2097

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site